AbbVie Shares Surge 1.59% on 32.33% Volume Spike as Expansion and Strong Earnings Push Stock to 91st in Trading Activity

AbbVie (ABBV) rose 1.59% to $204.68 on August 14, with a trading volume of $0.95 billion, a 32.33% increase from the prior day. The stock ranked 91st in trading activity, reflecting heightened investor interest amid recent developments.

The biopharmaceutical giant announced a $195 million investment to expand its North Chicago facility, boosting active pharmaceutical ingredient (API) production in the U.S. This move underscores AbbVie’s commitment to strengthening domestic manufacturing capabilities, aligning with growing demand for its immunology and neuroscience therapies. The expansion is expected to enhance operational efficiency and support long-term revenue growth.

Strong Q2 earnings further fueled optimism. The company reported adjusted earnings per share of $2.97, exceeding expectations, driven by robust sales of Skyrizi and Rinvoq. These newer immunology drugs are outpacing revenue declines from older products like Humira, reinforcing AbbVie’s strategic shift toward high-growth therapeutic areas. Management raised full-year profit guidance, signaling confidence in sustained performance.

Analysts noted potential catalysts, including the recent positive Phase 3 trial results for Rinvoq in treating alopecia areata and the submission of a combination therapy for chronic lymphocytic leukemia. These advancements highlight AbbVie’s innovation pipeline, which could drive market share gains in competitive therapeutic segments.

A strategy of purchasing the top 500 stocks by daily trading volume and holding for one day from 2022 to 2025 yielded a compound annual growth rate of 6.98%. However, the approach faced a maximum drawdown of 15.59% during the backtest period, emphasizing the need for risk management in high-volume trading strategies.